The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Just Published

JCP
Investigation of Appetite Hormones Illustrates Current Limitations of Psychiatric Diagnosis
Commentary

April 9, 2025

Commenting on an article by Hsu and colleagues, Dr Mischoulon discusses the current state and future potential of biomarkers in the understanding and treatment of mood disorders.
JCP
Ketamine Infusions and Written Exposure Therapy for Chronic PTSD
Original Research

April 2, 2025

Preliminary findings suggest that the combined treatment may yield large and durable symptom reductions for patients with severe chronic PTSD
, , , et al
JCP
Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study
Original Research

April 2, 2025

Suicidal ideations and neurocognitive disorders were the most frequent diagnostic impressions, with males at higher risk of neurocognitive and substance use disorders. Patients 85 or older were more likely…
, , , et al

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry’s Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD
View current Issue

Explore Special Sections

View all topics
Focus on Psychosis Focus on Geriatric Psychiatry Focus on Women’s Mental Health Focus on Suicide Early Career Psychiatrists Focus on Psychotherapy

Original Research

JCP
Parental Severe Mental Disorders and Deaths in Offspring With MDD
Original Research

March 31, 2025

Parental-Severe-Mental-Disorder-All-Cause-Suicide-Mortalities-Adolescent-Young-Adults-Major-Depressive-Disorder
, , , et al
JCP
Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia
Original Research

March 24, 2025

Xanomeline and trospium showed improvement in agitation as measured by the PANSS-Excited Component in participants with acute exacerbations of schizophrenia.
, , , et al
JCP
Pharmacokinetics of Olanzapine Intranasal Spray vs Olanzapine IM
Original Research

March 19, 2025

Two investigational intranasal formulations of olanzapine containing the permeation enhancer dodecyl maltoside showed favorable pharmacokinetics and an acceptable safety profile in healthy adults.
, , , et al

Review Articles

JCP
Treating PTSD in Military Populations
Meta-Analysis

March 24, 2025

Integrating psychotherapies and pharmacotherapies may address multiple dimensions of PTSD more effectively than monotherapies.
, , , et al
JCP
Changes in Cognition in Patients With Schizophrenia
Meta-Analysis

September 25, 2024

Only marginal improvements in cognition were seen over time; the greatest were achieved for patients with an illness duration shorter than 10 years.
, , , et al
JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
, , , et al
JCP
Cognitive Effects of ECT in Schizophrenia: A Review
Review Article

June 5, 2024

ECT was not associated with any significant cognitive deficits in people with treatment-resistant schizophrenia across global cognition, attention, language, visuospatial function, and executive function domains. The majority of studies…
,
JCP
Interpersonal Psychotherapy for PTSD: A Critical Review
Review Article

May 29, 2024

This critical review will give clinicians confidence in considering IPT as an alternative to exposure treatments for posttraumatic stress disorder.
JCP
Omega-3 PUFA Supplements for ADHD
Meta-Analysis

August 30, 2023

Although omega-3 polyunsaturated fatty acids (PUFAs) may not improve core symptoms of attention-deficit/hyperactivity disorder, longer-term PUFA supplementation may have potential benefits.
, , , et al

Read articles from ASCP Corner

ASCP Corner

Letters to the Editor

JCP
The Need for Clinical Guidance on Ketamine/Esketamine Use in Clinical Settings
Letter to the Editor

February 5, 2025

The authors comment on a recent study by Santucci et al.
,
JCP
Opioid Use Disorder in Sexually and Gender Diverse Populations: Can We Do Better?
Letter to the Editor

February 3, 2025

The authors respond to a recent JCP article by McDowell and colleagues.
, ,
JCP
Mental Health Assessment and Psychosocial Intervention in Maternal-Fetal Interventions
Letter to the Editor

November 18, 2024

In discussing a recent JCP letter to the editor, Akerson et al recommend that centers for fetal diagnosis and treatment include a social worker who can provide psychosocial assessment,…
, , , et al
JCP
Clarification Regarding the Psychiatrist’s Role—Reply to Akerson et al
Letter to the Editor

November 18, 2024

The authors respond to a letter by Akerson et al.
, , , et al
JCP
Detecting Misuse of Prescription Opioids
Letter to the Editor

October 21, 2024

The authors discuss the difficulty in screening for opioid misuse and the need for clinicians to gain confidence in initiating difficult discussions with patients on long-term opioid treatment.
, ,
JCP
Mental Health Assessments for Fetal Interventions
Letter to the Editor

June 24, 2024

The authors offer guidance and raise awareness about the intersection of maternal mental health and fetal interventions.
, ,

Commentaries

JCP
Eating Disorders Among Transgender and Gender Diverse People: Qualitative Analysis of Reddit Threads
Commentary

March 10, 2025

This subreddit analysis characterizes the body dissatisfaction and desire to eliminate gendered physical characteristics that transgender and gender diverse (TGD) people with eating disorders experience. Many on the subreddit…
, ,
JCP
A New Tool to Refine Lithium Therapy: Simple Formula for a Complex Problem
Commentary

March 3, 2025

The authors consider potential benefits and limitations of a new equation for estimating 12-hour serum lithium levels.
, ,
JCP
Back to the Office: The Room Where It Happens?
Commentary

March 3, 2025

The authors discuss in-person versus remote delivery of psychotherapy and present the findings of a survey characterizing current practice.
, , , et al
JCP
Xanomeline-Trospium Tolerability: Commentary
Commentary

February 26, 2025

The author discusses new findings from Kaul et al on the safety and tolerability of xanomeline-trospium.
JCP
SUD Programs for Transgender and Gender Diverse Patients
Commentary

November 11, 2024

The authors discuss responsiveness of transgender and gender diverse patients to SUD treatment at different care levels (eg, outpatient, residential, inpatient), as well as how to reduce stressors and…
,
JCP
Clinical Implications of Adult ADHD: What New Data Tell Us
Commentary

October 10, 2024

The authors discuss striking new findings from the Morbidity and Mortality Weekly Report on the burden of adult ADHD, demonstrating the need for the upcoming APSARD Adult ADHD Guidelines.
,

More JCP Articles

JCP
Joint Statement on Federal Concerns About Psychotropic Medication Safety

March 24, 2025

The safety and efficacy of traditional antidepressants, antipsychotics, and mood stabilizers (such as lithium and some anticonvulsants) and stimulant medications have been established through decades of rigorous research, randomized…
JCP
Infant Distress to Limitation and Postpartum Depression Treatment Response
Brief Report

March 19, 2025

Higher infant distress to limitation predicted higher postpartum depression symptoms following CBT, both at posttreatment and 3 months later.
, ,
JCP
Discordant Sibling Pair Comparisons
Clinical and Practical Psychopharmacology

March 17, 2025

Illustrative examples are used to explain what sibling studies are and how sibling comparisons can strengthen or weaken causal hypotheses in observational studies.
JCP
Negative Ethnic-Racial Identity and Internalizing Symptoms in Latiné Youth Exposed to Trauma
Original Research

March 17, 2025

In a large group of Latiné youth who had experienced trauma, negative affect about their ethnic racial identity not only was associated with worse internalizing symptoms, but also increased…
, , , et al
JCP
Suicide and Benzodiazepine Use in Veterans With Bipolar Disorder
Original Research

March 12, 2025

Among VHA patients diagnosed with bipolar disorder, receipt of a benzodiazepine prescription of ≥ 30 days was associated with increased suicide risk, even after controlling for clinical and demographic…
, , , et al
JCP
Plasma Biomarkers and Incident Mild Behavioral Impairment
Original Research

March 5, 2025

High baseline plasma p-tau181 levels were associated with a greater risk of incident mild behavioral impairment in multi-ethnic Asian older adults with mixed pathology over a 5-year period.
, , , et al
JCP
Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum
Original Research

March 5, 2025

Risks of a postpartum suicide attempt were increased 4- to 30-fold by clinical factors, including prenatal suicide attempt ED visits, psychiatric ED visits, and assault ED visits, and by…
, , , et al
JCP
Maintenance of Antidepressant Effect After 1 Dose of Psilocybin
Original Research

March 3, 2025

Over 52 weeks, a single administration of 25 mg psilocybin suggested longer maintenance of antidepressant effect than both 1 mg and 10 mg.
, , , et al
JCP
Estimating the 12-Hour Serum Lithium Level
Original Research

March 3, 2025

Lithium blood tests should be conducted 12 hours after the last lithium dose, but complying with this strict timing is difficult. The authors developed a simple tool to estimate…
, , , et al
JCP
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
Original Research

February 26, 2025

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic…
, , , et al
JCP
Update on Current & Emerging Treatments for Negative Symptoms in Schizophrenia
Insights

February 21, 2025

In this video, Dr. Kantrowitz provides an in-depth update on current and emerging treatments for the negative symptoms of schizophrenia. He discusses symptom classifications, key clinical trials, and potential…
JCP
The Near-Term Future of Muscarinic Agonists and Modulators for Schizophrenia: M1 and/or M4
Insights

February 21, 2025

In this video, Dr. Kantrowitz explores the potential of muscarinic acetylcholine receptor (mACHR) agonists and modulators for schizophrenia treatment, with a focus on M1 and M4 receptors. He reviews…

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe